Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana.
Pharmacotherapy. 2010 Aug;30(8):787-96. doi: 10.1592/phco.30.8.787.
To investigate the potential impact of proton pump inhibitors (PPIs) on the effectiveness of clopidogrel in preventing recurrent ischemic events after percutaneous coronary intervention (PCI) with stent placement.
Population-based, retrospective cohort study.
National medical and pharmacy benefit claims database comprising approximately 19 million members.
A total of 16,690 patients who had undergone PCI with stent placement and who were highly adherent to clopidogrel therapy alone (9862 patients) or to clopidogrel with a PPI (6828 patients) between October 1, 2005, and September 30, 2006.
The primary end point was the occurrence of a major adverse cardiovascular event during the 12 months after stent placement. These events were defined as hospitalization for a cerebrovascular event (stroke or transient ischemic attack), an acute coronary syndrome (myocardial infarction or unstable angina), coronary revascularization (PCI or coronary artery bypass graft), or cardiovascular death. A composite event rate was compared between patients who received clopidogrel alone and those who received concomitant clopidogrel-PPI therapy. Baseline differences in covariates were adjusted by using Cox proportional hazards models. In the 9862 patients receiving clopidogrel alone, 1766 (17.9%) experienced a major adverse cardiovascular event compared with 1710 patients (25.0%) who received concomitant clopidogrel-PPI therapy (adjusted hazard ratio 1.51, 95% confidence interval 1.39-1.64, p<0.0001). Similar associations of increased risk were observed for each PPI studied (omeprazole, esomeprazole, pantoprazole, and lansoprazole).
Concomitant use of a PPI and clopidogrel compared with clopidogrel alone was associated with a higher rate of major adverse cardiovascular events within 1 year after coronary stent placement.
探究质子泵抑制剂(PPIs)对经皮冠状动脉介入治疗(PCI)后支架置入患者氯吡格雷预防复发性缺血事件的效果的潜在影响。
基于人群的回顾性队列研究。
国家医疗和药品福利索赔数据库,包含约 1900 万成员。
2005 年 10 月 1 日至 2006 年 9 月 30 日期间,共 16690 例接受 PCI 支架置入且单独接受氯吡格雷高剂量治疗(9862 例)或氯吡格雷联合 PPI 治疗(6828 例)的患者。
主要终点为支架置入后 12 个月内主要不良心血管事件的发生。这些事件定义为因脑血管事件(中风或短暂性脑缺血发作)、急性冠状动脉综合征(心肌梗死或不稳定型心绞痛)、冠状动脉血运重建(PCI 或冠状动脉旁路移植术)或心血管死亡而住院。通过 Cox 比例风险模型比较接受氯吡格雷单独治疗的患者与同时接受氯吡格雷-PPI 治疗的患者的复合事件发生率。通过 Cox 比例风险模型调整了协变量的基线差异。在 9862 例单独接受氯吡格雷治疗的患者中,1766 例(17.9%)发生主要不良心血管事件,而同时接受氯吡格雷-PPI 治疗的 1710 例患者(25.0%)发生主要不良心血管事件(调整后的危险比 1.51,95%置信区间 1.39-1.64,p<0.0001)。研究中的每种 PPI(奥美拉唑、埃索美拉唑、泮托拉唑和兰索拉唑)均观察到类似的风险增加关联。
与单独使用氯吡格雷相比,氯吡格雷联合 PPI 治疗与冠状动脉支架置入后 1 年内主要不良心血管事件发生率升高相关。